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Abstract  
Novel   therapies   including   biologic   agents   offer   paediatric   rheumatologists  
significant   opportunity   to   improve   long-­term   prognosis   for   children   with  
rheumatic   disease.   However   co-­morbidities   related   to   the   diseases  
themselves   and   their   treatments,   pose   specific   challenges   to   be   overcome.    
Prompt   recognition  and  appropriate  management  will   improve  quality  of   life,  
effectiveness   of   treatment,   and   overall   prognosis.   In   this   review  we   discuss  
key  areas  of  co-­morbidity   frequently  encountered   in  paediatric   rheumatology  
including   cardiovascular,   renal,   genitourinary   and   visual   co-­morbidity,   bone  




The  care  of  children  and  young  people  with  severe,  often  rare,  multi-­system  
autoimmune   rheumatic   diseases   poses   a   significant   challenge   to   multi-­
disciplinary   specialist   teams   (MDST)   endeavoring   to   provide   holistic   care   to  
patients   and   their   families.   This   is   compounded   by   a   striking   paucity   of   a  
rigorous  evidence  base  for  their  management  [1].  Childhood  and  adolescence  
is  a  time  of  profound  biological  development  and  psychological  change  –  all  of  
which  confer  additional   impact  on  chronic,  complex   inflammatory  conditions.  
Many   drugs   used   to   treat   these   disorders   have   major   potential   short-­,  
medium-­  and  long-­term  side  effects  that  many  young  people  and  their  parents  
find   intolerable   [2].   Compounding   the   complexity   in   managing   paediatric  
rheumatic   disorders,   are   the   frequent   occurrence   of   single   or   multiple  
comorbidities.   These   can   impact   significantly   on   the   disease   process   itself,  
treatment   choices,   and   contribute   to   the   full   impact   of   the   problems   to   be  
faced  by  patients  and  their  families.  
  
Comorbid  conditions  may  be  directly  linked  to  the  underlying  disease  process  
itself  and  /  or  treatments,  or  may  occur   independently.   Increased  recognition  
and   efforts   to   appropriately   manage   comorbidities   is   driven   by   greater  
expectation  of  outcome,  the  significant  potential  impact  that  they  can  have  on  
quality   of   life,   and   the   improved   prognosis   of   the   primary   disease.   Diverse  
comorbid   conditions   influence   outcomes   differently;;   pulmonary   and   cardiac  
comorbidities  may  increase  mortality;;  whereas  localised  growth  abnormalities  
such  as  micrognathia  may  associate  with  low  mood  and  depression.  As  many  
outcome  studies   in  paediatric   rheumatology  predate   the  current  approaches  
to   treatment   it   is   not   easy   to   extrapolate   the   relevance   of   these   data   to  
patients   presenting   currently   [3,4].   Such   studies   can   also   be   difficult   to  
compare   due   to   differences   in   the   terminology   used   internationally   (e.g.  
juvenile   idiopathic   arthritis   (JIA),   juvenile   rheumatoid   arthritis   (JRA),   juvenile  
chronic   arthritis   (JCA)).   Notwithstanding   these   challenges,   we   discuss   key  
areas   of   co-­morbidity   frequently   encountered   in   paediatric   rheumatology,  
including  cardiovascular,   renal  and  visual  co-­morbidity,  bone  health,  and   the  
influence  of  rheumatic  disorders  and  treatment  on  growth  and  puberty.    
Cardiovascular  co-­morbidity  in  paediatric  rheumatic  disease  
Atherosclerosis   is   a   chronic   inflammatory   condition   itself   influenced   by  
rheumatic   disease-­related   factors   such   as   immune   complex   formation,  
complement   activation,   anti-­phospholipid   antibodies,   inflammation,  
corticosteroid   use   and   endothelial   dysfunction   [5-­8].   Significantly   increased  
mortality   from   cardiovascular   disease   reported   in   adults   with   rheumatic  
disease  is  likely  to  be  due  in  part  to  a  clinically  silent  atherosclerotic  process  
beginning   during   childhood.   In   JIA,   atherosclerotic   lesions   have   been  
demonstrated  in  post  mortem  specimens  of  children  [9].    
  
Carotid   intima-­media   thickness   (CIMT)   has   been   validated   against  
pathological   studies   to   assess   pre-­clinical   atherosclerotic   plaques   in   adults  
[10].      CIMT   is   increased   in   children   with   systemic-­onset   JIA,   juvenile-­onset  
systemic   lupus   erythematosus   (JSLE)   and   adults   with   a   history   of   juvenile  
dermatomyositis   (JDM),   compared   to   controls   [6,7,11,12].   Phase   contrast  
magnetic   resonance   imaging   (MRI)   demonstrates   aortic   compliance   and  
dispensability   is   reduced   in   JIA,   indicating   endothelial   dysfunction   and  
subclinical   atherosclerosis   [6].   Doppler   ultrasound   of   the   brachial   artery  
measuring  flow-­mediated  dilatation  (FMD)  is  impaired  in  children  with  JIA  and  
adults  with  JDM  as  compared  to  controls  [5,12].  Novel  methods  of  screening  
premature  atherosclerosis   in  young  people  such  as  static   /  dynamic  nail   fold  
video-­capillaroscopy  have  been  proposed  [9].  
  
The  prevalence  of   traditional   cardiovascular   risk   factors   (hypertension,  body  
mass   index,   hyperlipidemia,   impaired   glucose   tolerance,   reduced   aerobic  
fitness),   are  observed   in   children  with   rheumatic  diseases   [13-­5].  Studies  of  
lipid  metabolism   in  children  with  JSLE  demonstrate   that  dyslipoproteinaemia  
appears   inherent   to   the  disease  process  with  depressed  HDL,  and  elevated  
VLDL  cholesterol  and  triglycerides  [11].  Lipid  abnormalities  occur  early  in  the  
JSLE   disease   course   (within   the   first   4   years)   [13].   Treatment   with  
corticosteroids  exacerbates  dyslipoproteinaemia,   increasing   total  cholesterol,  
VLDL-­cholesterol   and   triglycerides   [14].   In   adults   with   SLE,  
hyperhomocysteinemia   is   implicated   in   the   pathogenesis   of   coronary   artery  
disease  and  linked  to  thromboembolic  events.  Studies  in  JSLE  have  reported  
raised   homocysteine   levels   although   further   prospective,   long-­term   studies  
are   required   to   further   elucidate   its   role   as   a   cardiovascular   risk   factor   in  
children  [16,17].  
Studies   of   atherosclerosis   prevention   in   paediatric   rheumatic   disease   are  
lacking.   As   children   and   young   people   with   rheumatic   disease   increasingly  
have   less   physical   and   functional   disability,   MDST’s   should   provide   advice  
and  encouragement   to   facilitate   lifestyle  changes,  which   reduce  obesity  and  
improve   fitness.   Use   of   hydroxychloraquine   has   been   associated   with  
reductions   in   cholesterol   and   apolipoprotein   B   levels   in   JSLE,   and   lower  
cholesterol,   low-­density   lipoprotein   levels   and   vascular   event   frequency   in  
adult  SLE  [18-­20].  Statin  use  is  reported  as  being  associated  with  a  variety  of  
inflammatory   myopathies,   and   is   consequently   usually   avoided   in   such  
conditions  [21].  
  
In   JSLE,   the   Atherosclerosis   Prevention   in   Pediatric   Lupus   Erythematosus  
(APPLE)   trial   [22]   randomised  patients   to  either  atorvastatin  or   placebo  and  
assessed   whether   3   years   of   treatment   was   effective   in   reducing  
atherosclerosis  progression  as  measured  by  CIMT.  Atorvastatin  did  not  have  
a   statistically   significant   effect   on   mean   CIMT   progression;;   however,   CIMT  
progression   rates  were   significantly   higher   in   the   placebo   group   than   those  
previously   reported   for   the   general   pediatric   population   and   children   with  
familial  hypercholesterolemia.  This  supports   the  view   that  JSLE  patients  are  
at   increased   risk   of   atherosclerosis.   Cholesterol   and   LDL   levels   also  
decreased  significantly  from  baseline  in  the  treatment  group.  Importantly,  the  
adverse  events  rate  was  comparable  between  treatment  and  placebo  groups  
over   the   3-­year   treatment   period   [22].   This   trial,   the   first   RCT   of   its   kind   in  
paediatric   rheumatic   disorders,   exemplifies   some   significant   challenges  
inherent  to  paediatric  research  that  compounds  the  challenges  of  addressing  
additional   issues   related   to   co-­morbidities   such   as   cardiovascular   risk   (see  
Table  1).  
  
Renal  and  genitourinary  co-­morbidity  in  paediatric  rheumatic  disease  
Co-­morbidity   due   to   renal   disease   is   more   prevalent   and   generally   more  
severe   in   JSLE  as   compared   to   adult-­onset   lupus,  with   up   to   80%  of   JSLE  
patients   having   renal   disease   at   some   point   in   their   disease   course   [24].  
There  is  significant  concern  that  irreversible  renal  damage  may  occur  prior  to  
the  onset  of  clinically  detectable  disease  [25,26].  Up  to  20%  of  children  with  
proliferative   lupus  nephritis   (LN)   develop   renal   failure   over   a   10-­year   period  
[27].  Potential  biomarkers  of  early  LN  disease,  disease   flares  and  predictors  
of  disease  remission  are  increasingly  being  studied  and  a  number  have  been  
identified   [28]   and   include:   urinary   monocyte   chemoattractant   protein-­1  
(MCP1),   Alpha-­1-­acid   glycoprotein   (AGP)   [29],   serum   CXC   motif   ligand   13  
(CXCL   13)   [30],   B-­cell   activating   factor   (BAFF),   regulated   upon   activation  
normal  T-­cell  expressed,  and  secreted  (RANTES),  soluble  vascular  adhesion  
molecule   1   (sVCAM-­1)   and   complement   fragments   Bb,   C3d-­CIC   and   C5.  
Complement   fragment  C1q   is   reduced   in  LN   [31].  The  optimal  biomarker  or  
combination  of  parameters  requires  further  longitudinal  analysis  to  determine  
which  are  best  at  predicting  LN  flares.  
Historically   renal   amyloidosis   was   a   major   complication   of   JIA   and   other  
paediatric  connective  tissue  disorders,  now  significantly  reduced  through  use  
of   intensive   immunosuppressive   treatment   regimens   [26].   ANCA-­associated  
glomerulonephritis   can   occur,   albeit   rarely   in   systemic-­onset   JIA   and   focal  
segmental  glomerulonephritis  /  mild  mesangial  glomerulonephritis  have  been  
reported  in  children  with  polyarticular  JIA  [32,33].  
Bone  health  in  paediatric  rheumatic  disease  
Decreased   bone  mineral   composition   (BMC)   and   density   (BMD)   along   with  
increased  fracture  risk  can  occur  in  children  with  rheumatic  diseases,  resulting  
in  considerable  pain  and  co-­morbidity   [34-­9].  Peak  bone  mass   is   reached  at  
the  end  of  adolescence  and  is  an  important  determinant  of  osteoporosis  and  
future   fracture   risk.   Multiple   factors   may   contribute   to   osteopenia,   including  
inflammation,  corticosteroid  use,  diseases  activity,  nutrition,  physical  inactivity,  
limited  exposure  to  sunlight  and  delays  in  pubertal  development,  all  potentially  
important  in  a  young  person  with  a  rheumatic  disorder  [34,35,39-­43].  Even  in  
the  absence  of  corticosteroid  treatment,  30%  of  post-­pubertal  female  patients  
with   mild-­to-­moderate   JIA   have   low   total   body   BMC   [39].   Similarly,   young  
adults   with   JIA   can   have   abnormal   BMD,   despite   achieving   full   disease  
remission  [44,45].  Further  studies  which  explore  potential  factors  contributing  
to  low  BMC  /  BMD  are  highlighted  in  Table  2.  
Studies   investigating   biochemical   markers   of   bone   turnover   in   JIA  
demonstrate   increased   bone   reabsorption   over   bone   formation,   although  
some   studies   show   a   reduction   in   bone   formation   only   [36,39,46].  
Abnormalities  in  bone  turnover  are  associated  with  increased  disease  activity,  
joint   destruction,   longer   disease   duration   and   pro-­inflammatory   cytokines  
[47,48].   Anti-­tumor   necrosis   factor   (TNF)   treatment   in   methotrexate   (MTX)-­
refractory   polyarticular   JIA   patients   is   associated   with   significant  
improvements  in  lumbar  spine  BMD  Z  score  and  bone  mineral  content  [49].  
A   negative   correlation   between   bone   mass   and   cumulative   glucocorticoid  
dose   occurs   in   children   with   variety   of   underlying   diseases   treated   with  
glucocorticoids   [50].   During   childhood   and   adolescence,   glucocorticoid  
treatment   impairs   bone   mass   accumulation,   leading   to   a   lower   peak   bone  
mass.  High  dose  MTX  in  cancer  treatment   is  associated  with  osteopenia  but  
does   not   negatively   influence   bone   mass   at   the   doses   used   in   paediatric  
rheumatic  diseases  [50].    
Bisphosphonates   are   an   effective   treatment   for   osteoporosis   in   adults,   with  
studies  showing  improvements  in  BMD  and  a  reduction  in  fracture  risk.  Much  
less   is   known   about   their   use   in   children.   A   recent   review   looking   at   the  
effectiveness  of  bisphosphonates  in  JIA  patients  with  fragility  fractures,  found  
treatment   to   increase  mean   spinal   BMD   by   4.5-­19.1%   [52].   Further   studies  
are   required   to  clarify  whether   these  positive  effects  continue  over   time,   the  
length  of  treatment  required,  the  maximal  bone  mass  that  can  occur  and  the  
long-­term  effect  on  fracture  risk   [52].  Calcium,  vitamin  D  and  calcitonin  have  
also  been  looked  at  in  small  studies  but  similarly  these  studies  do  not  address  
longer-­term  outcomes  [36].  
Physical   activity   is   a  major   non-­pharmacological  method   for   increasing   and  
maintaining   peak   BMD   and   strength.   Adults   who   participate   in   high   impact  
sports   and   exercises   have   a   higher   BMD   [53].   Studies   in   healthy   children  
have   supported   the   efficacy   of  weight   bearing   exercises   in   increasing  BMD  
[54].   Studies   addressing   the   amount,   duration   and   frequency   of   weight  
bearing  exercise,  along  with  safety  and  efficacy  of  such  exercise  regimens  in  
paediatric  rheumatic  disease  are  necessary.  Alcohol   intake  and  smoking  are  
associated   with   osteoporosis   and   increased   fracture   risk   and   should   be  
discussed  with  adolescent  patients  [55].    
Ophthalmological  complications  of  paediatric  rheumatic  disease  
Uveitis  occurs   in  12-­38%  of  JIA  patients   [56-­8],  often  asymptomatically.  The  
presence  of  uveitis  may  precede  the  development  of  arthritis,  and  often  flares  
of   uveitis   and   arthritis   do   not   co-­inside   [59]   emphasising   the   need   for   eye  
screening   [60].   Severe   JIA-­associated   uveitis   is   associated   with   cataracts,  
increased  intra-­ocular  pressure,  band  keratopathy  and  posterior  synechiae  in  
up  to  75%  of  cases  [59,61,62].  The  risk  of  developing  uveitis  varies  according  
to   the   subtype   of   JIA   with   patients   with   oligoarticular   disease   having   the  
highest   frequency   of   uveitis,   followed   by   polyarticular   and   systemic   onset  
subtypes   [59,61].  Other   risk   factors   include:   female  gender,   <6   years   old   at  
diagnosis  and  having  JIA   for  <4  years   [63].  Uveitis-­associated  complications  
are  more  likely  in  those  who  develop  chronic  uveitis,  psoriatic  JIA,  a  diagnosis  
of   uveitis   prior   to,   or   at   the   time   of   arthritis   onset,   or   in   patients   who   are  
symptomatic   at   the   time  of   uveitis   onset   [64].  Visual   outcomes  and   rates  of  
complications  in  JIA-­associated  uveitis  are  summarised  in  Table  3.  
  
Topical   corticosteroids   are   first-­line   treatment   of   JIA-­associated   uveitis  
although   complications   include:   increased   intraocular   pressure   and   cataract  
formation.  Systemic  corticosteroids  and  peri-­ocular  steroid   injections  may  be  
required   in   refractory   cases.   Increasingly   systemic   immunosuppressive  
agents   are   used   to   reduce   the   risks   of   sight   threatening   complications   and  
achieve   a   steroid   sparing   effect.   MTX   is   well   established   as   the   first   line  
disease-­modifying   agent   in   JIA;;   however,   15-­50%   of   children   will   have  
refractory   uveitis   despite   optimal   treatment   with  MTX   [67].   Anti-­TNF   agents  
vary  in  their  efficacy  in  severe  refractory  uveitis  [68],  and  reports  of  new-­onset  
uveitis-­associated  with  etanercept  use  in  JIA  [69]  has  lead  to  the  preferential  
use  of   infliximab  or  adalimumab   in  JIA  patients  with  uveitis.  When  treatment  
with  one  sub-­type  of  anti-­TNF  has  been  ineffective  switching  to  another  anti-­
TNF  agent  can  be  successful  in  achieving  control  of  intra-­ocular  inflammation  
[67].  
  
Growth  in  paediatric  rheumatic  disease    
Growth   disorders   are   common   in   children   with   chronic   rheumatic   diseases  
and  have  been  attributed  to  a  range  of  contributing  factors  including  disease  
duration  and  severity,  age  at  diseases  onset,  immobility,  sub-­optimal  nutrition  
and  corticosteroid   therapy.   In  JIA,   the  prevalence  of  significant  short  stature  
(final  height  z-­score  defined  as   less   than   twice   the  standard  deviation  score  
adjusted   for   age)   ranges   from   11%   of   all   JIA,   to   41%   of   patients   with  
systemic-­onset  disease  [3,70,71].  JSLE  patients  show  a  significant  reduction  
in  parent-­adjusted  height  z-­scores,  with  males  being  most  affected   [72].  The  
children  most  at  risk  of  having  a  height  deficit  were  those  that  presented  in  the  
pre-­pubertal   /   peri-­pubertal   period,   who   were   treated   with   >400mg/kg  
cumulative   dose   of   corticosteroids.   Further   follow-­up   studies   exploring   the  
effects  of  biologics,  steroid-­sparing  regimens  and  improved  disease  control  on  
growth  are  warranted.  
Growth   hormone   (GH)   and   insulin   like   growth   factor   (IGF-­1)   are   the   most  
important   regulators  of   growth  out  with   the  neonatal   period.   In   children  with  
JIA  and  significant  growth  impairment,  low  levels  of  IGF-­1  are  described  with  
normal   on-­going   pulsatile   GH   secretion   [36,73].   Table   4   describes   the  
relationship   between   the   inflammatory   cytokines   implicated   in   rheumatic  
disease  and  hormonal   regulators  of  growth.  JIA  patients   treated  with  GH  for  
one  year  can  achieve  a  significant  increase  in  height  velocity  [75].  In  children  
with  systemic  and  polyarticular  JIA,  GH  therapy   improves  height  velocity  but  
not  necessarily  the  predicted  target  height  (final  height  z-­score  -­1.6  in  treated  
patients   and   -­3.4   in   controls)   [76].   GH   therapy   for   children   with   severe   JIA  
receiving   12-­15   months   of   steroid   treatment   can   normalise   height   velocity  
during  the  first  year  of  treatment,  remaining  normal  over  the  subsequent  two  
years   [77].   Collectively   these   studies   suggest   that   GH   improves   short-­term  
height   velocity   but   may   not   entirely   reverse   the   effects   of   treatment   and  
underlying  disease  on  growth.  
  
The  pattern  of  growth  disturbance  in  JIA  can  be  generalised  or  localised  and  
tends   to   vary   according   to   the   subtype.  More   severe   JIA   is   associated  with  
generalised  growth  impairment.  Oligoarticular  JIA  typically  can  be  associated  
with   increased   growth   in   the   affected   limb   in   young   children   and   decrease  
growth   due   to   premature   fusion   of   the   epiphyses   in   older   children   [73-­4]  
resulting   in   limb   or   digit   length   discrepancy,   or   micrognathia.      In   practice,  
growth   retardation,   especially   localised   is   felt   to   be   becoming   less   common  
with  current  treatment  approaches,  and  often  is  a  feature  of  delay  in  access  to  
specialist  care.  Growth  can  be  reversibly  impaired  during  periods  of  intensive  
steroid   therapy   [78]   although   full   catch-­up   growth   is   not   always   attained  
following  cessation  of  steroid  treatment  [79].    
  
The   impact   of   anti-­TNF   treatment   on   growth   velocity   has   been   studied   in  
polyarticular   JIA   patients.   Those   with   delayed   growth   before   anti-­TNF  
treatment  displayed  a  significant  increase  in  growth  velocity  at  two  years  after  
commencing   treatment   [80].  When  glucocorticoid   dosage  was   corrected   for,  
the   change   in   inflammatory   activity   emerged   as   a   significant   predictor   of  
growth  velocity,  suggesting  that  reduced  inflammation  affected  growth  velocity  
rather   than   the   anti-­TNF   treatment   having   a   direct   effect   on   growth.  
Comparing  growth  velocity  in  new  polyarticular  JIA  patients  treated  with  MTX  
alone   and   patients   who   had   etanercept   added   to   MTX   treatment   due   to  
inadequate   disease   control,   indicates   growth   velocity   only   increases  
significantly   in   the   group   receiving   etanercept   [49].   Similarly,   looking   at  
polyarticular   and   systemic-­onset   JIA   patients   treated   with   etanercept,  
etanercept   and   MTX   or   MTX   alone   for   three   years,   statistically   significant  
increases   in  mean  height  were  only  seen   in   those  who  received  etanercept,  
with  or  without  MTX  [81].  
  
Puberty  in  paediatric  rheumatic  disease  
Pubertal  delay  has  been  reported  widely  in  adolescents  with  paediatric  onset  
rheumatic  diseases.   In  JSLE,  pubertal  onset  may  be  delayed   in  as  many  as  
15%  and  24%  of   the   female  and  male   JSLE  patients   respectively   [73].   In  a  
Brazilian   study   involving   30   patients   with   JSLE   and   30   matched   controls,  
mean  menarchal  age  was  13.1  years   in   lupus  patients  versus  11.6  years   in  
controls  [82].  A  high  prevalence  of  menstrual  disturbance  is  reported  in  JSLE,  
varying   from   irregular   menses,   long   cycle   lengths   to   postmenarche  
amenorrhea  [72,82].    The  hormone  profiles  of  adolescent  females  with  JSLE  
differ   from   healthy   controls,   with   increased   median   follicle   stimulating  
hormone   levels   and   lower   median   progesterone   levels   [82].   In   JIA,   age   of  
onset  of  menarche  has  been  compared  between  patients  and  their  mothers,  
revealing   the   timing   of   menarche   to   also   be   later   in   JIA   and   particularly  
delayed   in   patients   who   had   systemic   /   polyarticular   JIA   or   received  
glucocorticoids  [83].    
Quality  of  life  
Chronic   illnesses   can   lead   to   significant   physical   and   psychosocial   co-­
morbidity.  Paediatric  rheumatologists  have  increasingly  become  aware  of  the  
need   to   measure   health-­related   quality   of   life   (HRQOL).   A   number   of  
assessments  can  be  used  to  do  this,  including  the  Child  Health  Questionnaire  
(CHQ)   and   Pediatric   Quality   of   Life   Inventory   (PedsQL)   [84,85].   Three  
international   studies   have   assessed   HRQOL   and   its   determinants   in   JIA,  
JSLE   and   JDM   [77,86,87].   In   all   three   studies,   significant   impairment   of  
HRQOL   was   identified   in   the   physical   domains   of   the   CHQ.   Physical   well-­
being  was  correlated  with  the  degree  of  functional  impairment  [86-­8],  whereas  
pain   had   the   greatest   influence   on   psychosocial   health   [86].   Patients   with  
persistent   oligoarthritis   had  better  HRQOL  compared  with  other   subtypes  of  
JIA,   whereas   patients   with   systemic   arthritis,   polyarthritis,   and   extended  
oligoarthritis   had   similar   HRQOL   [86].   In   JSLE,   the   Systemic   Lupus  
Erythematosus   Disease   Activity   Index   (SLEDAI)   score   was   significantly  
correlated  with   the  physical   and  psychosocial   summary   scores  of   the  CHQ.  
The  Systemic   Lupus   International  Collaborating  Clinics/American  College   of  
Rheumatology   Damage   Index   (SDI)   score   was   also   significantly   correlated  
with   the   physical   summary   score,   suggesting   that  HRQOL   in   JSLE  may   be  
affected  by  disease  activity  and  accumulated  damage   [87].      In   JDM,  poorer  
physical  and  psychosocial   summary  scores  were  associated  with   increasing  
levels  of  disease  activity  and  reduced  muscle  strength  [88].    
QOL  assessment  in  adults  with  all  types  of  JIA  indicates  a  profound  effect  on  
generic  health  status  and  QOL  at  a  median  age  of  30  years.  Despite  excellent  
educational  attainment,  a  high  rate  of  unemployment  amongst  these  patients  
can  exist   [89,90].  The  challenge  with  modern   therapies  and   transitional  care  
programmes   is   to   improve   outcomes   relevant   to   patient   priorities   –   being  
employed  has  considerable   impact  on  well  being  and  QOL  but   the   impact   in  
adult   cohorts   may   not   be   fully   evident   until   years   to   come,   when   these  
patients  reach  their  third  and  fourth  decade.    
Drug  related  co-­morbidity  
Many  medications   used   in   paediatric   rheumatology   can   have   potential   side  
effects.  Non-­steroidal   anti-­inflammatory   drugs   (NSAIDs)   are   associated  with  
acute   kidney   injury,   hypertension   and   interstitial   nephritis   in   children.   A  
prospective  study  evaluating  renal  complications  in  JIA  patients  treated  for  ≥6  
months   with   NSAIDs   found   22/226   children   (10%)   had   microscopic  
haematuria   and/or   proteinuria   on   >1   urinalysis.   No   patients   developed  
hypertension  and  in  21/22  patients  the  abnormalities  resolved  spontaneously  
[91].    
MTX   is   one   of   the   most   useful   and   commonly   used   drugs   in   paediatric  
rheumatology  due  to  its  efficacy  and  the  availability  of   long-­term  safety  data.  
Intolerance  to  MTX,  namely  nausea  and  vomiting,  stomach  ache,  sore  mouth  
and  behavioral   symptoms  may  occur   in  up   to  44%  of   JIA  patients   receiving  
oral  MTX  and  67%  receiving  parenteral   treatment  [92].  Symptoms  can  occur  
after   taking   MTX,   prior   to   (anticipatory),   and   when   thinking   of   MTX  
(associative).     Newer  biologic  treatments  have  transformed  the  management  
of   JIA   patients   with   MTX   intolerance   and  MTX-­resistant   disease.   However,  
with   an   increasing   number   of   clinical   trials   and   the   consistent   availability   of  
these   agents   only   within   recent   years,   longer-­term   safety   data   are   not  
available,  and  their  long-­term  use  as  first  line  agents  remain  cautionary.    
In  2009,   the  Food  and  Drugs  Association  (FDA)   issued  a  warning  related   to  
the  potential  development  of  malignancies  in  patients  with  JIA  who  had  used  
anti-­TNF  medications  for  more  than  2.5  years.  This  was  based  on  a  study  that  
included   48   children   with   both   JIA   and   inflammatory   bowel   disease   who  
developed   cancer   whilst   receiving   anti-­TNF   therapy   and   other  
immunosuppressive   agents.   These   findings   clearly   cannot   be   ignored,   but  
recent   data   suggest   that   JIA   per   se   and   not   the   exposure   to   MTX   or  
biolologics   may   associate   with   an   increase   risk   of   malignancy   [93].   In  
rheumatoid   arthritis   (RA),   evidence   has   accumulated   that   disease   activity  
itself  is  associated  with  risk  of  lymphoma  [94].  Observational  studies  exploring  
the   link  between  anti-­TNF   treatment  and  cancer   risk  have  not   indicated  any  
increased   risk   of   cancer,   although   the   follow-­up   periods   have   been   rather  
short   (mean   follow-­up   of   3   years)   [95].   More   investigation   in   this   matter   is  
therefore  warranted.  Biologics  Registries  in  the  UK  and  elsewhere  have  been  
collecting   information   on   long-­term   safety   and   effectiveness   of   biological  
agents  in  patients  with  rheumatic  diseases  since  2000.  Longer-­term  follow-­up  
and   collaborative   collation   of   data   internationally   is   necessary   to   improve  
reliability   of   these   observations   and   fully   address   the   concerns   regarding  
paediatric  rheumatic  disease,  biologic  treatment  and  malignancy.  
Cyclophosphamide  is  used  to  treat  severe  manifestations  of  JSLE,  JDM  and  
vasculitis.   Bladder   toxicity,   cancer   and   haemorrhagic   cystitis   are   seen   in  
oncology   patients   where   prolonged   courses   of   oral   cyclophosphamide   are  
used.   In   autoimmune   rheumatic   diseases   where   intermittent   intravenous  
cyclophosphamide   is  used  such  complications  are  rarely  seen.  Lowering  the  
cumulative   dose,   concomitant   use   of   MESNA,   intravenous   therapy   and  
adequate  hydration  are  all  important  in  minimising  risks  [96].  Increased  risk  of  
cervical   dysplasia   is   associated   with   cyclophosphamide   use   in   SLE.   It   is  
important   that   young   women   with   lupus   follow   established   guidelines   for  
cervical  cancer  screening  and  human  papilloma  virus  vaccination  [97,98].  
Mortality  associated  with  paediatric  rheumatic  disease  
Studies  looking  at  mortality  in  paediatric  rheumatic  disease  are  largely  unable  
to  determine  the  influence  of  co-­morbid  disease  on  mortality  due  to  the  lack  of  
adequate   longitudinal   follow-­up.  Adults  with  a  history  of  JIA  and  a  co-­morbid  
autoimmune  disease   (e.g.  autoimmune  hepatitis,   insulin  dependent  diabetes  
mellitus,  common  variable  immunodeficiency,  graves  disease)  have  a  shorter  
life  expectancy  than  age  and  sex-­matched  members  of  the  general  population  
[99].   Data   from   the   Indianapolis   paediatric   rheumatology   registry   [100]   has  
been   used   to   describe   the   standardized   mortality   ratio   (SMR,   ratio   of  
observed   deaths   to   expected   deaths)   and   causes   of   death   of   a   cohort   of  
paediatric   rheumatology  patients   (49,023  patients   studied  between1993  and  
2001).  The  SMR  was  increased  in  patients  with  JSLE  and  JDM  (3.06  [95%  CI  
1.78–4.90]   and   2.64   [95%  CI   0.86–6.17]   respectively).   For   patients   with   all  
types  of   JRA,  SMR  was   less   than   that  of   the  cohort  as  a  whole.  Causes  of  
death  were  related  to  the  underlying  rheumatic  disease  and  it’s  complications  
in  35%,  and  treatment  complications  in  a  further  10%  of  patients.  
Transition    
Transition   from  paediatric   to   adolescent   to   adult   rheumatology   services   is   a  
particularly   challenging   time   when   young   people   are   expected   to   take  
increasing   responsibility   for   their   own   health   and   well-­being;;   however   the  
difficulties  many  young  people   face   is  exemplified  by   reduced  adherence   to  
treatment  regimes,  risk  taking  behaviours  and  worse  clinical  outcomes.  Timely  
discussions  must  be  held  between  MDST  professionals  and  young  people  to  
improve   their  awareness  of   long-­term  co-­morbidities,  which  may  be   reduced  
by   modifying   lifestyle   factors   (such   as   healthy   eating,   regular   exercise,  
avoidance   of   smoking   and   limiting   alcohol   intake)   as   well   as   optimal  
adherence  to  treatment  regimes.    
Conclusion  
The   holistic   care   of   children   and   young   people   with   complex,   chronic  
rheumatic   disorders   is   by   definition   complex   and   challenging.   Identification  
and   management   of   co-­morbidity   in   paediatric   rheumatic   disease   is  
increasingly   becoming   important   with   improving   medical   therapies   and  
approaches   to   treatment.   Novel   therapies   including   biologic   agents   provide  
significant   opportunity   to   improve  quality   of   life  and   long-­term  prognosis.  By  
raising  awareness  of  the  importance  of  co-­morbid  conditions  this  review  aims  
to   focus   and   direct   paediatric   and   adult   rheumatologists   to   address   their  
current   care   and   practice.   Potential   complications   and   co-­morbid   conditions  
arising   from   these   disorders   and   their   treatment   regimens   require   specific  
attention  at  an  early  stage,  especially  as  clinical  effects  may  only  be  apparent  
in  the  distant  future.  It  is  therefore  imperative  that  we  consider  co-­morbidities  
sooner   rather   than   later   in   order   to   further   improve   long-­term   patient  
outcomes.   Lifestyle   issues   are   likely   to   be   important   and   need   to   be  
addressed   in   generic   health   advice.   Specific   challenges   to   overcome   the  
paucity  of  an  evidence  base  to  direct  care  of  these  co-­morbid  conditions  must  
be   addressed   to   determine   optimal   standards   of   care   for   comorbid   disease  
prevention.   This   requires   proactive   national   and   international   collaborative  
efforts   of   researchers   across   different   disciplines   in   prospective,   long-­term,  
collaborative  follow-­up  studies.  
  
Key  messages  
•   Identification   of   co-­morbidity   is   increasingly   important  with   improvements  
in  the  prognosis  of  underlying  paediatric  rheumatic  diseases. 
•   The   evidence   base   underpinning   co-­morbidity   management   must   be  
addressed  to  determine  optimal  standards  of  care. 
•   Long-­term  observational  studies  spanning  the  transition  period  are  key  to  
addressing  these  issues.    
References  
1.   Thornton   J,   Beresford   MW,   Clayton   P.   Improving   evidence   base   for  
treatment  of  JIA:  the  challenge  and  opportunity  facing  the  MCRN/ARC  
Paediatric  Rheumatology  Clinical  Studies  Group.  Rheumatology  2008;;  
47(5):563-­566.  
2.   Beresford   MW,   Davidson   JE.   Adolescent   development   and   SLE.  
Chapter   10   in:   Best   Practice   &   Research   in   Clinical   Rheumatology  
2006;;  20(2):  353-­368.  
3.   Minden  K.  Adult  outcomes  of  patients  with   juvenile   idiopathic  arthritis.  
Horm  Res  2009;;  72(suppl  1):20-­5.  
4.   Minden  K,  Niewerth  M,  Listing  J  et  al.  Long-­term  outcome   in  patients  
with  juvenile  idiopathic  arthritis.  Arthritis  Rheum  2002;;  46:2392-­2401.    
5.   Vlahos   AP,   Theocharis   P,   Bechlioulis   A   et   al.   Changes   in   vascular  
function  and  structure  in  juvenile  idiopathic  arthritis.  Arthritis  Care  Res  
2011;;  63(12):1736-­44.    
6.   Argyropoulou  MI,  Kiortsis  DN,  Daskas  N  et  al.  Distensibility  and  pulse  
wave   velocity   of   the   thoracic   aorta   in   patients  with   juvenile   idiopathic  
arthritis:  an  MRI  study.  Clin  Exp  Rheumatol  2003;;  21(6):794-­7.  
7.   Haque  S,  Gordon  C,  Isenberg  D  et  al.  Risk  factors  for  clinical  coronary  
heart   disease   in   systemic   lupus   erythematosus:   the   lupus   and  
atherosclerosis   evaluation   of   risk   (LASER)   study.   J  Rheumatol   2010;;  
37(2):322-­9.    
8.   Doria   A,   Shoenfeld   Y,   Wu   R   et   al.   Risk   factors   for   subclinical  
atherosclerosis  in  a  prospective  cohort  of  patients  with  systemic  lupus  
erythematosus.  Ann  Rheum  Dis  2003;;  62:1071–1077.    
9.   Górska   A,   Rutkowska-­Sak   L,   Musiej-­Nowakowska   E   et   al.   Nailfold  
videocapillaroscopy   -­  a  useful   tool   for  screening  patients  with   juvenile  
idiopathic   arthritis   at   the   risk   of   development   of   premature  
atherosclerosis.  Postepy  Hig  Med  Dosw  2010;;  64:296-­302.  
10.  Mancini   J,   Dahlöf   B,   Díez   J.   Surrogate   Markers   for   Cardiovascular  
Disease  Structural  Markers.  Circulation  2004;;  109(5):22-­30.  
11.  Falaschi  F,  Ravelli  A,  Martignoni  A  et  al.  Nephrotic   range  proteinuria,  
the  major  risk  factor  for  early  atherosclerosis  in  juvenile-­onset  systemic  
lupus  erythematosus.  Arthritis  Rheum  2000;;  43  (6):1405–1409.  
12.  Eimer   MJ,   Brickman   WJ,   Seshadri   R   et   al.   Clinical   Status   and  
Cardiovascular   Risk   Profile   of   Adults   with   a   History   of   Juvenile  
Dermatomyositis.  J  Pediatr  2011;;  159:795-­801.    
13.  Hayata  AL,  Borba  EF,  Bonfá  E  et  al.  The  frequency  of  high/moderate  
lipoprotein   risk   factor   for   coronary   artery   disease   is   significant   in  
juvenile-­onset   systemic   lupus  erythematosus.  Lupus  2005;;  14(8):613-­
7.  
14.  Ilowite   NT.   Hyperlipidemia   and   the   rheumatic   diseases.   Curr   Opin  
Rheumatol  1996;;  8:455–8.  
15.  Goff  I,  Coulson  E,  Foster  H.  Adults  with  Juvenile  Idiopathic  Arthritis  are  
at   Increased   Cardiovascular   Risk.   Rheumatology   2011;;   50(suppl   3):  
iii90-­iii91.  
16.  Do   Prado   R,   D'Almeida   VM,   Guerra-­Shinohara   E.   Increased  
concentration  of  plasma  homocysteine   in  children  with  systemic   lupus  
erythematosus.  Clin  Exp  Rheumatol  2006;;  24(5):594-­8.  
17.  Terreri  MT,  Sarni  RO,  Do  Prado  R.    Hyperhomocysteinemia  in  children  
and   adolescents   with   systemic   lupus   erythematosus:   evolutive  
evaluation.  Acta  Reumatol  Port  2008;;  33(1):57-­62.  
18.  Boros   CA,   Bradley   TJ,   Cheung   MM   et   al.   Early   determinants   of  
atherosclerosis   in   paediatric   systemic   lupus   erythematosus.   Clin   Exp  
Rheumatol  2011;;  29(3):575-­81.  
19.  Sazliyana   S,   Mohd   Shahrir   MS,   Kong   CT   et   al.   Implications   of  
immunosuppressive   agents   in   cardiovascular   risks   and   carotid   intima  
media   thickness   among   lupus   nephritis   patients.   Lupus   2011;;  
20(12):1260-­6.  
20.  Becker-­Merok   A,   Nossent   J.   Prevalence,   predictors   and   outcome   of  
vascular   damage   in   systemic   lupus   erythematosus.   Lupus   2009;;  
18(6):508-­15.  
21.  Padala  S,  Thompson  PD.  Statins  as  a  possible  cause  of  inflammatory  
and   necrotizing   myopathies.   Atherosclerosis   2011   published   on   16t  
Nov.  dx.doi.org/10.1016/j.atherosclerosis.2011.11.005  
22.  Schanberg   LE,   Sandborg   C,   Barnhart   HX   et   al.   Atherosclerosis  
Prevention   in   Pediatric   Lupus   Erythematosus   Investigators.   Use   of  
atorvastatin   in   systemic   lupus   erythematosus   in   children   and  
adolescents.  Arthritis  Rheum  2012;;  64(1):285-­96.    
23.  Petri   MA,   Kiani   AN,   Post  W   et   al.   Lupus   Atherosclerosis   Prevention  
Study  (LAPS).  Ann  Rheum  Dis  2011;;  70(5):760-­5.  
24.  Watson   L,   Leone   V,   Pilkington   C   et   al.   Juvenile-­onset   SLE:   disease  
activity,   severity   and   damage   -­   The  UK   JSLE  Cohort   Study.   Arthritis  
Rheum  2012  published  on  31  January  2012.  doi:  10.1002/art.34410.    
25.  Tucker   LB,  Uribe  AG,   Fernández  M   et   al.   Adolescent   onset   of   lupus  
results   in  more  aggressive  disease  and  worse  outcomes:   results  of  a  
nested  matched  case control  study  within  LUMINA,  a  multiethnic  US  
cohort  (LUMINA  LVII).  Lupus  2008;;  17:  314-­22.  
26.  Immonen  K,  Finne  P,  Grönhagen-­Riska  C  et   al.  A  marked  decline   in  
the  incidence  of  renal  replacement  therapy  for  amyloidosis  associated  
with  inflammatory  rheumatic  diseases  -­  data  from  nationwide  registries  
in  Finland.  Amyloid.  2011;;  18(1):25-­8.  
27.  Baqi   N,   Moazami   S,   Singh   A   et   al.   Lupus   nephritis   in   children:   a  
longitudinal  study  of  prognostic  factors  and  therapy.  J  Am  Soc  Nephrol  
1996;;  7:  924–929.  
28.  Watson   L,   Beresford   MW.   Urine   biomarkers   in   Juvenile-­onset   SLE  
nephritis.  J  Paediatr  Nephrol  2012  (In  Press).  
29.  Watson   L,   Midgley   A,   Pilkington   C   et   al.   Urinary   monocyte  
chemoattractant  protein  1  and  alpha  1  acid  glycoprotein  as  biomarkers  
of   renal   disease   activity  in   juvenile-­onset   systemic   lupus  
erythematosus.   Lupus   2011   published   on   6   December   2011,   doi:  
10.1177/0961203311431249.  
30.  Ezzat  M,  El-­Gammasy  T,  Shaheen  K.  Elevated  production  of  serum  B-­
cell-­attracting   chemokine-­1   (BCA-­1/CXCL13)   is   correlated   with  
childhood-­onset  lupus  disease  activity,  severity,  and  renal  involvement.  
Lupus  2011;;  20(8):845-­54.    
31.  Edelbauer  M,  Kshirsagar  S,  Riedl  M  et  al.  Markers  of  childhood  lupus  
nephritis   indicating   disease   activity.   Pediatr  Nephrol   2011;;   26(3):401-­
10.  
32.  Gedalia  A,  Mendez  EA,  Craver  R  et  al.  Renal   involvement   in   juvenile  
rheumatoid   arthritis:   report   of   two   cases.   Clin   Rheumatol   2001;;  
20(2):153-­6.  
33.  Belot   A,   Bader-­Meunier   B,   Niaudet   P.   ANCA-­Associated  
Glomerulonephritis   in  Systemic-­Onset  Juvenile   Idiopathic  Arthritis.  Am  
J  Kidney  Dis  2011;;  59(3):439-­43.    
34.  Compeyrot-­Lacassagne  S,  Tyrrell  PN,  Atenafu  E  et  al.  Prevalence  and  
etiology   of   low   bone   mineral   density   in   juvenile   systemic   lupus  
erythematosus.  Arthritis  Rheum  2007;;  56(6):1966-­73.  
35.  Gunhild   Lien   G,   Berit   Flatø   B,   Haugen   M   et   al.   Frequency   of  
osteopenia   in  adolescents  with  early-­onset   juvenile   idiopathic  arthritis:  
A   long-­term   outcome   study   of   one   hundred   five   patients.   Arthritis   &  
Rheum  2003;;  48(8):  2214–2223.  
36.  Maresova   KB,   Secondary   Osteoporosis   in   Patients   with   Juvenile  
Idiopathic   Arthritis.   Journal   of   Osteoporosis   2011   published   on   8th  
January  2011.  doi:10.4061/2011/569417  
37.  Zak   M,   Hassager   C,   Lovell   DJ   et   al.   Assessment   of   bone   mineral  
density   in   adults   with   a   history   of   juvenile   chronic   arthritis:   a   cross-­  
sectional   long-­term   follow-­up   study.   Arthritis   &  Rheumatism   1999;;   42  
(4):790–798,  1999.  
38.  Markula-­Patjas  KP,  Valta  HL,  Kerttula  LI  et  al.  Prevalence  of  vertebral  
compression   fractures   and   associated   factors   in   children   and  
adolescents  with  severe  juvenile  idiopathic  arthritis.  J  Rheumatol  2012;;  
39(2):365-­73.    
39.  Henderson  CJ,   Specker   BL,   Sierra  RI   et   al.   Total-­body   bone  mineral  
content  in  non–corticosteroid-­treated  postpubertal  females  with  juvenile  
rheumatoid  arthritis:  Frequency  of  osteopenia  and  contributing  factors.  
Arthritis  &  Rheum  2000;;  43  (3):  531-­40.  
40.  Alsufyani  KA,  Ortiz-­Alvarez  O,  Cabral  DA  et  al.  Bone  mineral  density  in  
children  and  adolescents  with  systemic   lupus  erythematosus,   juvenile  
dermatomyositis,   and   systemic   vasculitis:   relationship   to   disease  
duration,  cumulative  corticosteroid  dose,  calcium  intake,  and  exercise.  
The  Journal  of  Rheumatology  2005;;  32(4):729-­733.  
41.  Castro   TCM,   Terreri   MT,   Szejnfeld   VL   et   al.   Bone   density   in   JSLE  
Bone   mineral   density   in   juvenile   systemic   lupus   erythematosus.  
Brazilian   Journal   of  Medical   and   Biological   Research   2002;;   35:1159-­
1163.  
42.  Stewart   WA,   Acott   PD,   Salisbury   SR   et   al.   Bone   mineral   density   in  
juvenile  dermatomyositis:  Assessment  using  dual  x-­ray  absorptiometry.  
Arthritis  &  Rheumatism  2003;;  48(8):2294–8.  
43.  Kashef   S,   Saki   F,   Karamizadeh   Z   et   al.   Bone   mineral   density   in  
children   with   systemic   lupus   erythematosus   and   juvenile   rheumatoid  
arthritis.  Ann  Saudi  Med  2007;;  27(6):427-­31.  
44.  Haugen  M,  Lien  G,  Flatøetal  B.  Young  adults  with   juvenile  arthritis   in  
remission   attain   normal   peak   bone   mass   at   the   lumbar   spine   and  
forearm.  Arthritis  &  Rheumatism  2000;;  43(7):1504-­10.  
45.  Thornton   J,  Pye  SR,  O’Neill   TW  et   al.  Bone  health   in   adult  men  and  
women  with  a  history  of  Juvenile  Idiopathic  Arthritis.  J  Rheumatol  2011;;  
38(8):  p.  1689-­1693.  
46.  Pepmueller  PH,  Cassidy   JT,  Allen  SH  et   al.   Bone  mineralization   and  
bone  mineral  metabolism  in  children  with   juvenile  rheumatoid  arthritis.  
Arthritis  &  Rheumatism  1996;;  39  (5):746–757.  
47.  Gorshka   A,   Urban   M,   Bartnick   M   et   al.   Bone   mineral   metabolism   in  
children   with   juvenile   idiopathic   arthritis.   Ortopedia   Traumatologia  
Rehabilitacja  2008;;  10(1):54–62.    
48.  Goldring   SR.   Pathogenesis   of   bone   and   cartilage   destruction   in  
rheumatoid  arthritis.  Rheumatology  2003;;  42(2):11–16.  
49.  Billiau  AD,  Loop  M,  Le  PQ  et  al.  Etanercept  improves  linear  growth  and  
bone   mass   acquisition   in   MTX-­resistant   polyarticular-­course   juvenile  
idiopathic  arthritis.  Rheumatology  2010;;  49(8):1550-­8.    
50.  Bianchi  ML.  Glucorticoids  and  bone:  some  general  remarks  and  some  
special  observations  in  pediatric  patients.  Calcified  Tissue  International  
2002;;  70(5):384–390.  
51.  Cranney  AB,  McKendry  RJ,  Wells  G.  A.  et  al.  The  effect  of   low  dose  
methotrexate   on   bone   density.   Journal   of   Rheumatology   2001;;  
28(11):2395-­9.  
52.  Thornton   J,   Ashcroft   DA,   Mughal   MZ   et   al.   Systematic   review   of  
effectiveness   of   bisphosphonates   in   treatment   of   low   bone   mineral  
density   and   fragility   fractures   in   juvenile   idiopathic   arthritis.   Arch   Dis  
Child  2006;;  91:753–761.  
53.  Bailey  CA,  Brooke-­Wavell  K.  Exercise   for  optimising  peak  bone  mass  
in  women.  Proc  Nutr  Soc  2008;;  67(1):9-­18.  
54.  Gannotti  ME,  Nahorniak  M,  Gorton  GE   et   al.   Can   exercise   influence  
low  bone  mineral  density  in  children  with  juvenile  rheumatoid  arthritis?  
Pediatr  Phys  Ther  2007;;  19(2):128-­39.  
55.  Bogoch   ER,   Elliot-­Gibson   V,   Wang   RY   et   al.   Secondary   Causes   of  
Osteoporosis  in  Fracture  Patients.  J  Orthop  Trauma  2012  published  on  
25th  February  2012.  doi:10.1097/BOT.0b013e3182323f2c  
56.  Kotaniemi   K,   Kautiainen   H,   Karma   A   et   al.   Occurrence   of   uveitis   in  
recently   diagnosed   juvenile   chronic   arthritis:   a   prospective   study.  
Ophthalmology  2001;;  108:2071-­5.  
57.  Saurenmann  RK,  Levin  AV,  Feldman  BM  et  al.  Prevalence,  risk  factors,  
and  outcome  of  uveitis  in  juvenile  idiopathic  arthritis:  a  long-­term  follow-­
up  study.  Arthritis  Rheum  2007;;  56:647-­57.  
58.  Qian   Y,   Acharya   NR.   Juvenile   idiopathic   arthritis   associated   uveitis.  
Curr  Opin  Ophthalmol  2010;;  21(6):  468–472.  
59.  Grassi   A,   Corona   F,   Casellato   A   et   al.   Prevalence   and   outcome   of  
juvenile   idiopathic   arthritis-­associated   uveitis   and   relation   to   articular  
disease.  J  Rheumatol  2007;;  34(5):1139-­45.  
60.  British  Society  of  Paediatric  and  Adolescent  Rheumatology  guidelines.  
BSPAR  guidelines  for  eye  screening.  
  www.bspar.org.uk/clinical-­guidelines  
61.  Skarin   A,   Elborgh   R,   Edlund   E.   Long-­term   follow-­up   of   patients   with  
uveitis  associated  with  juvenile  idiopathic  arthritis:  a  cohort  study.  Ocul  
Immunol  Inflamm  2009;;  17(2):104-­8.  
62.  Sabri  K,  Saurenmann  RK,  Silverman  ED.  Course,   complications,   and  
outcome  of  juvenile  arthritis-­related  uveitis.  J  AAPOS  2008;;  12(6):539-­
45.  
63.  Kaha  P.   Juvenile   Idiopathic  Arthritis.   Bulletin   of   the  NYU  Hospital   for  
Joint  Diseases  2011;;  69(3):  264-­76.  
64.  Cabral  DA,  Petty  RE,  Malleson  PN  et  al.  Visual  prognosis   in  children  
with   chronic   anterior   uveitis   and   arthritis.   J   Rheumatol.   1994;;  
21(12):2370-­5.  
65.  Woreta   F,   Thorne   JE,   Jabs   DA   et   al.   Risk   factors   for   ocular  
complications   and   poor   visual   acuity   at   presentation   among   patients  
with   uveitis   associated   with   juvenile   idiopathic   arthritis.   Am   J  
Ophthalmol  2007;;  143(4):647–55.  
66.  Ayuso  VK,  Ten  Cate  HA,  Van  Der  Does  P  et  al.  Male  gender  and  poor  
visual   outcome   in   uveitis   associated   with   juvenile   idiopathic   arthritis.  
Am  J  Ophthalmol  2010;;  149(6):987–93.  
67.  Simonini  G,  Cantarini   L,  Bresci  C.  Current   therapeutic   approaches   to  
autoimmune   chronic   uveitis   in   children.   Autoimmunity   Reviews   2010;;  
9:674–683.  
68.  Saurenmann   RK,   Levin   AV,   Rose   JB   et   al.   Tumour   necrosis   factor  
alpha   inhibitors   in   the   treatment   of   childhood   uveitis.   Rheumatology  
2006;;  45:982-­9.  
69.  Taban  M,  Dupps  WJ,  Mandell  B  et  al.  Etanercept   (enbrel)-­associated  
inflammatory  eye  disease:  case  report  and  review  of  the  literature.  Ocul  
Immunol  Inflamm  2006;;  14:145-­50.  
70.  Simon   D,   Fernando   C,   Czernichow   P   et   al.   Linear   growth   and   final  
height  in  patients  with  systemic  juvenile  idiopathic  arthritis  treated  with  
long  term  glucocorticoids.  J  Rheumatol  2002;;  29:1296-­300.  
71.  Aggarwal   B,   Bhalla   AK,   Singh   S.   Longitudinal   growth   attainments   of  
Indian   boys   with   Juvenile   Rheumatoid   Arthritis.   Rheumatol   Int   2011;;  
31:635-­40.  
72.  Rygg  M,   Pistorio   A,   Ravelli   A   et   al.   A   longitudinal   PRINTO   study   on  
growth   and   puberty   in   juvenile   systemic   lupus   erythematosus.   Ann  
Rheum  Dis  2012;;  71(4):511-­517.  
73.  MacRae  VE,   Farquharson  C,  Ahmed  SF.  The   pathophysiology   of   the  
growth   plate   in   juvenile   idiopathic   arthritis.   Rheumatology   2006;;  
45(1):11-­19.  
74.  Gaspari   S,   Marcovecchio   ML,   Breda   L   et   al.   Growth   in   juvenile  
idiopathic  arthritis:  the  role  of  inflammation.  Clin  Exp  Rheumatol  2011;;  
29(1):104-­10.  
75.  Davies   UM,   Rooney   M,   Preece   MA   et   al.   Treatment   of   growth-­
retardation  in  juvenile  chronic  arthritis  with  recombinant  human  growth-­
hormone.  J  Rheumatol  1994;;  21:153–8.  
76.  Bechtold   S,   Ripperger   P,   Dalla   Pozza   R   et   al.   Growth   Hormone  
Increases   Final   Height   in   Patients   with   Juvenile   Idiopathic   Arthritis:  
Data   from   a   Randomized   Controlled   Study.   The   Journ   of   Clin  
Endocrinol  &  Metab  2007;;  92  (8):  3013-­8.  
77.  Simon  D,  Prieur  AM,  Quartier  P  et  al.  Early  recombinant  human  growth  
hormone   treatment   in   glucocorticoid-­treated   children   with   juvenile  
idiopathic  arthritis:  a  3-­year  randomized  study.  J  Clin  Endocrinol  Metab  
2007;;  92(7):  2567-­73.  
78.  Ahmed   SF,   Tucker   P,   Mushtaq   T   et   al.   Short-­term   effects   on   linear  
growth  and  bone  turn  in  children  randomized  to  receive  prednisolone  or  
dexamethasone.  Clin  Endocrinol  2002;;  57:185-­91.    
79.  Simon  D,  Lucidarme  N,  Prieur  A-­M  et  al.  Treatment  of  growth  failure  in  
Juvenile  chronic  arthritis.  Horm  Res  2002;;  58:28-­32.    
80.  Tynjala  P,  Lahdenne  P,  Vahasalo  P  et  al.  Impact  of  anti-­TNF  treatment  
on  growth  in  severe  juvenile  idiopathic  arthritis.  Ann  Rheum  Dis  2006;;  
65:1044–1049.    
81.  Giannini  EH,  Ilowite  NT,  Lovell  DJ  et  al.  Effects  of  long-­term  etanercept  
treatment   on   growth   in   children   with   selected   categories   of   juvenile  
idiopathic  arthritis.  Arthritis  Rheum  2010;;  62(11):3259-­64.    
82.  Medeiros   PB,   Febrônio   MV,   Bonfá   E   et   al.   Menstrual   and   hormonal  
alterations   in   juvenile   systemic   lupus   erythematosus.   Lupus   2009;;  
18:38–43.  
83.  Rusconi   R,   Corona   F,   Grassi   A   et   al.   Age   at   menarche   in   juvenile  
rheumatoid  arthritis.  J  Pediatr  Endocrinol  Metab  2003;;16(Suppl  2):285-­
8.  
84.  Varni   JW,   Seid   M,   Smith   KT   et   al.   The   PedsQL   in   pediatric  
rheumatology:   reliability,   validity,   and   responsiveness   of   the  Pediatric  
Quality   of   Life   Inventory   Generic   Core   Scales   and   Rheumatology  
Module.  Arthritis  Rheum  2002;;  46(3):714-­25.  
85.  Varni  JW,  Burwinkle  TM,  Seid  M  et  al.  The  PedsQL  4.0  as  a  pediatric  
population   health   measure:   feasibility,   reliability,   and   validity.   Ambul  
Pediatr  2003;;  3(6):329-­41.  
86.  Oliveira   S,   Ravelli   A,   Pistorio   A   et   al.   American   College   of  
Rheumatology   Proxy-­Reported   Health-­Related   Quality   of   Life   of  
Patients  With  Juvenile  Idiopathic  Arthritis:  The  Pediatric  Rheumatology  
International   Trials   Organization   Multinational   Quality   of   Life   Cohort  
Study.  Arthritis  &  Rheum  2007;;  57(1):35–43.  
87.  Ruperto  N,  Buratti  S,  Duarte-­Salazar  C.  Health-­Related  Quality  of  Life  
in  Juvenile-­Onset  Systemic  Lupus  Erythematosus  and  Its  Relationship  
to  Disease  Activity  and  Damage.  Arthritis  &  Rheum  2004;;  51(3),  458–
64.  
88.  Apaz  MT,  Saad-­Magalha  C,  Pistorio  A.  Health-­Related  Quality  of  Life  
of  Patients  With  Juvenile  Dermatomyositis:  Results  From  the  Paediatric  
Rheumatology  International  Trials  Organisation  Multinational  Quality  of  
Life  Cohort  Study.  Arthritis  &  Rheum  2009;;  61(4):509–517.  
89.  Foster   HE,   Marshall   N,   Myers   A.   Outcome   in   Adults   With   Juvenile  
Idiopathic   Arthritis.  A   Quality   of   Life   Study.   Arthritis   Rheum  2003;;  
48(3):767–75.    
90.  Packham  JC,  Hall  MA.  Long-­term  follow-­up  of  246  adults  with  juvenile  
idiopathic   arthritis:   education   and   employment.   Rheumatology   2002;;  
41(12):1436-­9.  
91.  Szer   IS,   Goldenstein-­Schainberg   C,   Kurtin   PS.   Paucity   of   renal  
complications  associated  with  non-­steroidal  anti-­inflammatory  drugs   in  
children  with  chronic  arthritis.  J  Pediatr  1991;;  119(5):815-­7.  
92.  Bulatović   M,   Heijstek   MW,   Verkaaik   M.   High   prevalence   of  
methotrexate   intolerance   in   juvenile   idiopathic   arthritis:   development  
and   validation   of   a   methotrexate   intolerance   severity   score.   Arthritis  
Rheum  2011;;  63(7):2007-­13.    
93.  Beukelman  T,  Haynes  K,  Curtis  et  al.  Rates  of  malignancy  associated  
with  juvenile  idiopathic  arthritis  and  its  treatment.  Arthritis  Rheum  2012;;  
64(4):1263-­71.  
94.  Baecklund  E,  Ekbom  A,  Feltelius  N  et  al.  Disease  activity  and   risk  of  
lymphoma   in   patients   with   rheumatoid   arthritis:   nested   case   control  
study.  BMJ  1998;;  317(7152):180-­1.  
95.  Rosenblum  H,  Amital  H.  Anti-­TNF  therapy:  Safety  aspects  of  taking  the  
risk.  Autoimmunity  Reviews  2011;;  10:563-­8.  
96.  Monach   PA,   Arnold   LM,   Merkel   PA.   Incidence   and   prevention   of  
bladder   toxicity   from  cyclophosphamide   in   the   treatment  of   rheumatic  
diseases:  A  data-­driven  review.  Arthritis  &  Rheum  2010;;  62(1):9-­21.  
97.  Ognenovski  VM,  Marder  W,  Somers  EC  et  al.   Increased   incidence  of  
cervical   intraepithelial   neoplasia   in   women   with   systemic   lupus  
erythematosus   treated   with   intravenous   cyclophosphamide.   J  
Rheumatol  2004;;  31(9):1763-­7.  
98.  Bernatsky  S,  Ramsey-­Goldman  R,  Clarke  AE.  Malignancy  in  Systemic  
Lupus   Erythematosus:   What   have   we   learned?   Best   Pract   Res   Clin  
Rheumatol  2009;;  23(4):  539–547.  
99.  French  AR,  Mason  T,  Nelson  AM  et  al.  Increased  mortality   in  adults  
with  a  history  of  juvenile  rheumatoid  arthritis:  a  population-­based  study.  
Arthritis  Rheum  2001;;  44:523-­527.  
100.  Hashkes   PJ,   Wright   BM,   Lauer   MS.   Mortality   Outcomes   in   Pediatric  
Rheumatology  in  the  US.  Arthritis  Rheumatism  2010;;  62(2):599–608.  
